Exploring the tumor immune microenvironment in ovarian cancer: a way-out to the therapeutic roadmap.

IF 4.6 2区医学 Q1 PHARMACOLOGY & PHARMACY

Expert Opinion on Therapeutic Targets Pub Date : 2023-07-01 Epub Date: 2023-09-15 DOI:10.1080/14728222.2023.2259096

Basharat Ahmad Bhat, Ifra Saifi, Nizar A Khamjan, Syed Suhail Hamdani, Abdullah Algaissi, Safeena Rashid, Mohammed M Alshehri, Showkat Ahmad Ganie, Mohtashim Lohani, Siddig Ibrahim Abdelwahab, Sajad Ahmad Dar

{"title":"Exploring the tumor immune microenvironment in ovarian cancer: a way-out to the therapeutic roadmap.","authors":"Basharat Ahmad Bhat, Ifra Saifi, Nizar A Khamjan, Syed Suhail Hamdani, Abdullah Algaissi, Safeena Rashid, Mohammed M Alshehri, Showkat Ahmad Ganie, Mohtashim Lohani, Siddig Ibrahim Abdelwahab, Sajad Ahmad Dar","doi":"10.1080/14728222.2023.2259096","DOIUrl":null,"url":null,"abstract":"Introduction: Despite cancer treatment strides, mortality due to ovarian cancer remains high globally. While immunotherapy has proven effective in treating cancers with low cure rates, it has limitations. Growing evidence suggests that both tumoral and non-tumoral components of the tumor immune microenvironment (TIME) play a significant role in cancer growth. Therefore, developing novel and focused therapy for ovarian cancer is critical. Studies indicate that TIME is involved in developing ovarian cancer, particularly genome-, transcriptome-, and proteome-wide studies. As a result, TIME may present a prospective therapeutic target for ovarian cancer patients.Areas covered: We examined several TIME-targeting medicines and the connection between TIME and ovarian cancer. The key protagonists and events in the TIME and therapeutic strategies that explicitly target these events in ovarian cancer are discussed.Expert opinion: We highlighted various targeted therapies against TIME in ovarian cancer, including anti-angiogenesis therapies and immune checkpoint inhibitors. While these therapies are in their infancy, they have shown promise in controlling ovarian cancer progression. The use of 'omics' technology is helping in better understanding of TIME in ovarian cancer and potentially identifying new therapeutic targets. TIME-targeted strategies could account for an additional treatment strategy when treating ovarian cancer.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"841-860"},"PeriodicalIF":4.6000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Therapeutic Targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14728222.2023.2259096","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/15 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Despite cancer treatment strides, mortality due to ovarian cancer remains high globally. While immunotherapy has proven effective in treating cancers with low cure rates, it has limitations. Growing evidence suggests that both tumoral and non-tumoral components of the tumor immune microenvironment (TIME) play a significant role in cancer growth. Therefore, developing novel and focused therapy for ovarian cancer is critical. Studies indicate that TIME is involved in developing ovarian cancer, particularly genome-, transcriptome-, and proteome-wide studies. As a result, TIME may present a prospective therapeutic target for ovarian cancer patients.

Areas covered: We examined several TIME-targeting medicines and the connection between TIME and ovarian cancer. The key protagonists and events in the TIME and therapeutic strategies that explicitly target these events in ovarian cancer are discussed.

Expert opinion: We highlighted various targeted therapies against TIME in ovarian cancer, including anti-angiogenesis therapies and immune checkpoint inhibitors. While these therapies are in their infancy, they have shown promise in controlling ovarian cancer progression. The use of 'omics' technology is helping in better understanding of TIME in ovarian cancer and potentially identifying new therapeutic targets. TIME-targeted strategies could account for an additional treatment strategy when treating ovarian cancer.

查看原文本刊更多论文

探索卵巢癌症的肿瘤免疫微环境：通往治疗路线图的途径。

简介：尽管癌症治疗取得了长足进步，但癌症导致的死亡率在全球范围内仍然很高。虽然免疫疗法已被证明在治疗治愈率低的癌症方面有效，但它也有局限性。越来越多的证据表明，肿瘤免疫微环境（TIME）的肿瘤和非肿瘤成分在癌症生长中发挥着重要作用。因此，开发新的和有针对性的治疗卵巢癌症是至关重要的。研究表明，TIME参与了卵巢癌症的发展，尤其是基因组、转录组和蛋白质组的研究。因此，TIME可能为卵巢癌症患者提供一个前瞻性的治疗靶点。涵盖的领域：我们研究了几种TIME靶向药物以及TIME与癌症之间的联系。讨论了《时代》杂志中的主要主角和事件以及明确针对卵巢癌症中这些事件的治疗策略。专家意见：我们强调了针对卵巢癌症TIME的各种靶向治疗，包括抗血管生成疗法和免疫检查点抑制剂。虽然这些疗法尚处于起步阶段，但它们在控制癌症进展方面显示出了前景。“组学”技术的使用有助于更好地了解卵巢癌症的时间，并有可能确定新的治疗靶点。在治疗卵巢癌症时，时间靶向策略可以解释额外的治疗策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Therapeutic Targets 医学-药学

CiteScore

8.90

自引率

1.70%

发文量

审稿时长

3 months

期刊介绍： The journal evaluates molecules, signalling pathways, receptors and other therapeutic targets and their potential as candidates for drug development. Articles in this journal focus on the molecular level and early preclinical studies. Articles should not include clinical information including specific drugs and clinical trials. The Editors welcome: Reviews covering novel disease targets at the molecular level and information on early preclinical studies and their implications for future drug development. Articles should not include clinical information including specific drugs and clinical trials. Original research papers reporting results of target selection and validation studies and basic mechanism of action studies for investigative and marketed drugs. The audience consists of scientists, managers and decision makers in the pharmaceutical industry, academic researchers working in the field of molecular medicine and others closely involved in R&D.